AU Patent

AU2017232227B2 — Novel antitumoral use of cabazitaxel

Assigned to Sanofi Mature IP · Expires 2019-06-06 · 7y expired

What this patent protects

NOVEL ANTITUMORAL USE OF CABAZITAXEL AVENTIS PHARMA S.A. Abstract The invention relates to a compound of formula: CH3 o O O CH3 H3C -- H C CH 0 HC HN,,- CH which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its …

USPTO Abstract

NOVEL ANTITUMORAL USE OF CABAZITAXEL AVENTIS PHARMA S.A. Abstract The invention relates to a compound of formula: CH3 o O O CH3 H3C -- H C CH 0 HC HN,,- CH which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017232227B2
Jurisdiction
AU
Classification
—
Expires
2019-06-06
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Mature IP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.